AIT BIOSCIENCE: Global Diagnostics Partnering Terms and Agreements 2014-2020

Z

ORGANIZATIONS IN THIS STORY

LETTER TO THE EDITOR

Have a concern or an opinion about this story? Click below to share your thoughts.
Send a message

Community Newsmaker

Know of a story that needs to be covered? Pitch your story to The Business Daily.
Community Newsmaker

AIT Bioscience issued the following announcement on May 18.

Global Diagnostics Partnering Terms and Agreements 2014-2020

The "Global Diagnostics Partnering Terms and Agreements 2014-2020" report has been added to ResearchAndMarkets.com's offering.

This report provides comprehensive understanding and unprecedented access to the diagnostic partnering agreements entered into by the world's leading companies.

Trends in Diagnostics dealmaking in the biopharma industry since 2014

Analysis of Diagnostics deal structure

Access to headline, upfront, milestone and royalty data

Case studies of real-life Diagnostics deals

Access to Diagnostics contract documents

Leading Diagnostics deals by value since 2014

Most active Diagnostics dealmakers since 2014

The report provides a detailed understanding and analysis of how and why companies enter Diagnostics partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes.

This report provides details of the latest Diagnostics agreements announced in the life sciences since 2014.

The report takes the reader through a comprehensive review Diagnostics deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Diagnostics partnering deals.

The report presents financial deal term values for Diagnostics deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Diagnostics partnering field; both the leading deal values and most active Diagnostics dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 2,400 online deal records of actual Diagnostics deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of Diagnostics dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Diagnostics dealmaking since 2014, including details of headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Diagnostics deals since 2014. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Diagnostics dealmaking with a brief summary followed by a comprehensive listing of Diagnostics deals announced by that company, as well as contract documents, where available.

Chapter 5 provides a comprehensive and detailed review of Diagnostics partnering deals signed and announced since Jan 2014, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of Diagnostics partnering deals signed and announced since Jan 2014. The Chapter is organized by specific Diagnostics technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

A comprehensive series of appendices is provided organized by Diagnostics partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Diagnostics partnering and dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Diagnostics technologies and products.

Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What is the payment structure for the deal?

How are sales and payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

Companies Mentioned

2bPrecise

3D Signatures

3M

3PrimeDx

4D Molecular Therapeutics

5-Diagnostics

7D Surgical

10X Genomics

14M Genomics

20/20 GeneSystems

23andMe

36 Strategies General Trading

1717 Life Science Ventures

A*STAR Agency for Science

Technology and Research

A*STAR Institute of Microelectronics (IME)

AAM Healthcare

AB Analitica

Abaxis

Abbott Laboratories

Abbvie

Abcam

Abcodia

Abionic

Abramson Cancer Center

Acacia Research

Accelerate Diagnostics

Access BIO

AccuGenomics

Accuray

AccuRef Diagnostics

Accu Reference Medical Laboratory

Accuscience

AceCGT Life Science

Achaogen

AC Immune

Acon Labs

Acoustic MedSystems

Actelion

ACT Genomics

Acumen Pharmaceuticals

Acutus Medical

AdAlta

Adaptiiv

Adaptive Biotechnologies

ADC Therapeutics

ADMA Biologics

Admera Health

ADS

ADT Altona Diagnostic Technologies

Advanced Accelerator Applications

Advanced Animal Diagnostics

Advanced Biological Laboratories

Advanced Cell Diagnostics

Advanced Chemistry Development

Advanced Cooling Therapy

Advanced Genomic Solutions

Advanced Guidance Technologies

Advanced Medical German Company of Kuwait

Advanced Nuclear Medicine Ingredients

ADx Healthcare

Aelan Cell Technologies

Aerocrine

Aethlon Medical

Aetna

Affinium Pharmaceuticals

AFFiRiS

Affymetrix

Agena Bioscience

Agendia

Agfa HealthCare

Agilent Technologies

Agiomix FZ

Agios Pharmaceuticals

AG Mednet

Agricultural Research Service

AIM Specialty Health

Aircraft Medical

Air Force General Hospital

Air Force Research Laboratory

AirStrip Technologies

AIT Laboratories

Akers Biosciences

Akili Interactive Labs

Akonni Biosystems

AKSA Medical

Albany Molecular Research

Albert Einstein Healthcare Network

Aldeyra Therapeutics

Alere

Alexion Pharmaceuticals

Alibaba Health

Align Technology

AliveCor

ALK-Abello

Allakos

Allegheny Technologies

Allele Biotechnology and Pharmaceuticals

Allergan

AllerGenis

Alliance Global FZ

Alliance Global Group

Alliance Pharma

Allied Healthcare Products

Almac Diagnostics

Almac Group

Alnylam Pharmaceuticals

Alphaeon

Alpha Imaging

Alpinion Medical Systems

ALR Technologies

Alteris

Altris

Alverno Clinical Laboratories

Al Zahrawi Medical Supplies

Alzheimer's Association

Alzheimer's Drug Discovery Foundation

Alzheimers Research UK

Amarantus BioSciences

Amazon Web Services

Ambry Genetics

AMD Insight

A Menarini Diagnostics

America's Choice Provider Network

American Animal Hospital Association

American Diabetes Association

American Health Imaging

American Lung Association

American Medical Systems

American Pathology Partners

Amerinet

Amgen

Amos Gazit

Amoy Diagnostics

AmoyDx Diagnostics

Amplitech

AmpTec

AMRA

Amydis Diagnostics

Analogic

Analytics 4 Life

Analytics Engines

Anapure BioScientific

Anavex Life Sciences

Angle

Angsana Molecular & Diagnostics

Anika Therapeutics

Anixa Biosciences

Annoroad

Anpac Bio-Medical Science

Antaros Medical

Antech

Anteo Diagnostics

Anthem Bluecross

Apax Partners

Aperiomics

Apogenix

Appistry

Apple

and many, many more!

For more information about this report visit https://www.researchandmarkets.com/r/ukkgz4

View source version on businesswire.com:https://www.businesswire.com/news/home/20200518005497/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: BIOTECHNOLOGY SCIENCE HEALTH OTHER SCIENCE

SOURCE: Research and Markets

Copyright Business Wire 2020.

PUB: 05/18/2020 10:04 AM/DISC: 05/18/2020 10:04 AM

http://www.businesswire.com/news/home/20200518005497/en

Original source can be found here.

ORGANIZATIONS IN THIS STORY

LETTER TO THE EDITOR

Have a concern or an opinion about this story? Click below to share your thoughts.
Send a message

Community Newsmaker

Know of a story that needs to be covered? Pitch your story to The Business Daily.
Community Newsmaker

MORE NEWS